Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.36 |
| ▸ | PPARG | P37231 | 6/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | AGXT | P21549 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27536785 | 0.85 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4PPARAPPARG | |
| SCHEMBL12287404 | 0.84 | PPARA (0.36) | PPARAPPARGFFAR1TDP1IDO1 | |
| SCHEMBL2551854 | 0.83 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4PPARAPPARG | |
| SCHEMBL2580854 | 0.82 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4PPARAPPARG | |
| SCHEMBL2557410 | 0.82 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4PPARAPPARG | |
| SCHEMBL14668157 | 0.78 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4PPARAPPARG | |
| SCHEMBL2557004 | 0.76 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4PPARAPPARG | |
| SCHEMBL13430494 | 0.73 | PPARA (0.41) | PPARAPPARGIDO1 | |
| SCHEMBL11224068 | 0.73 | IDO1 (0.48) | SLC6A2SLC6A3SLC6A4PPARAPPARG | |
| SCHEMBL13430495 | 0.71 | AGXT (0.40) | PPARAPPARGFFAR1TDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029980-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | SLC6A2 3041/4885SLC6A3 2847/4885SLC6A4 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.